HIMS vs VEEV: Weighing Consumer Telehealth Momentum Against Enterprise Software Stability
Key Takeaways
- HIMS is a fast-growing, direct-to-consumer telehealth and wellness platform, while VEEV is a profitable, recurring-revenue cloud software provider for the life sciences industry.
- HIMS posted roughly 59% revenue growth in its most recent fiscal year but faces regulatory uncertainty tied to compounded GLP-1 (glucagon-like peptide-1) weight-loss medications.
- VEEV grows at a steadier double-digit pace, with recent quarterly revenue up about 16% year over year and operating margins near 30%.
- HIMS carries higher volatility, while VEEV offers more established profitability and a lower-risk, subscription-based business model.
- Relative performance has diverged: HIMS is shaped by consumer-demand and regulatory catalysts, whereas VEEV is driven by enterprise software adoption and AI product expansion.
- For additional context on each name, review HIMS Major News and HIMS Today's Price Move, along with VEEV Major News and VEEV Today's Price Move.
- Explore Trending AI Robots to review AI-powered trading strategies currently favored by Tickeron's platform.
Introduction
This comparison looks at two healthcare-adjacent growth companies that operate in quite different parts of the market. HIMS (Hims & Hers Health) is a consumer-oriented telehealth business expanding quickly yet dealing with regulatory questions, whereas VEEV (Veeva Systems) is a more mature enterprise software provider focused on pharmaceutical and biotech clients. The contrast matters most for investors deciding between higher-growth, higher-volatility opportunities and steadier, profitable recurring-revenue models. Growth-focused traders may lean toward HIMS and its catalysts, while those preferring stability and predictable cash flow could find VEEV more suitable.
HIMS Overview and Recent Performance
HIMS, or Hims & Hers Health, runs a multi-specialty telehealth platform that provides prescription medications, mental-health support, dermatology, sexual-health treatments, and more recently weight-loss products. The company has expanded rapidly, reporting full-year revenue near $2.3 billion in its latest fiscal year, up roughly 59%, with subscribers exceeding 2.5 million. Growth has centered on personalized and weight-loss offerings, although the company notes that the majority of U.S. revenue now comes from non-GLP-1 products. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent trading has shown notable volatility. The removal of semaglutide from the FDA's drug shortage list introduced uncertainty around compounded GLP-1 sales, a key growth area, and led to a meaningful pullback from prior highs. The stock maintains a high beta, indicating larger price swings relative to the broader market. In recent weeks, mixed earnings—with revenue beating estimates but guidance coming in softer—along with talks with Novo Nordisk about offering branded obesity treatments have influenced sentiment. Margin pressure from infrastructure spending continues to draw attention.
VEEV Overview and Recent Performance
VEEV, or Veeva Systems, supplies cloud software, data, and consulting solutions designed specifically for the global life sciences sector. Its offerings include the Development Cloud for clinical, regulatory, and safety applications, the Commercial Cloud with CRM and analytics, and the Data Cloud. The business generates recurring subscription revenue from pharmaceutical, biotech, and medical-device customers and has maintained consistent profitability.
Performance has been steady amid some challenges. Quarterly revenue has increased about 16% year over year, with non-GAAP earnings surpassing expectations and operating margins near 30%. Demand for system modernization, the Crossix analytics platform, and early AI features has supported growth. Sentiment has softened due to concerns over potential CRM customer transitions and a share-price decline in recent months. Management continues to highlight diversification and AI product development as central to ongoing progress. From what I see, VEEV’s subscription model provides a clearer view of future revenue streams.
Head-to-Head Comparison
The core difference lies in their business models. HIMS sells directly to consumers and remains sensitive to marketing efficiency, customer-acquisition costs, and regulatory changes in telehealth and weight-loss treatments. VEEV sells enterprise software on a subscription basis, which delivers more predictable recurring revenue and higher operating margins. This distinction largely accounts for their different risk profiles: HIMS shows elevated beta and margins compressed to low single digits, while VEEV sustains margins near 30% and a more stable earnings foundation.
Growth drivers also vary. HIMS focuses on platform expansion across new categories and addressing the GLP-1 regulatory overhang through partnerships and diversification. VEEV relies on enterprise digital transformation, data-analytics demand, and a multi-year AI roadmap. Both operate in healthcare spaces, yet HIMS targets consumer telehealth while VEEV serves B2B life-sciences technology. Market sentiment has been uneven for both recently—HIMS due to regulatory and guidance issues, VEEV due to CRM migration questions—though their volatility levels remain clearly distinct.
Tickeron AI Verdict
Considering factors such as trend consistency, margin stability, and revenue predictability, Tickeron’s AI would likely lean toward VEEV in the current setting. Veeva’s steadier growth, stronger profitability, and recurring subscription model offer a more consistent technical and fundamental profile compared with HIMS’s higher-volatility, catalyst-driven approach. At the same time, HIMS could deliver greater upside for momentum-oriented traders if regulatory clarity on GLP-1 products improves or partnership developments emerge. The AI’s assessment remains probabilistic, reflecting the trade-off between VEEV’s stability and HIMS’s higher-growth, higher-risk positioning.
Using Tickeron AI Trading Bots for Strategy Ideas
In my own review process, I often turn to Tickeron’s AI Trading Bots to test how different automated strategies perform across volatile names like these. The platform’s bots cover a range of hold periods, risk levels, and stock universes, allowing me to match approaches to specific objectives without sorting through every option manually. This helps add a layer of quantitative perspective to the fundamental and technical analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for VEEV turns positive, indicating new upward trend
VEEV saw its Momentum Indicator move above the 0 level on September 23, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 58 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for VEEV just turned positive on October 09, 2026. Looking at past instances where VEEV's MACD turned positive, the stock continued to rise in 31 of 53 cases over the following month. The odds of a continued upward trend are 58%.
Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in 179 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 137 of 210 cases where VEEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
VEEV broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.038) is normal, around the industry mean (4.198). VEEV has a moderately high P/E Ratio (52.103) as compared to the industry average of (13.596). Projected Growth (PEG Ratio) (1.248) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (12.739) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Why Do You Want to Own the Shares of a Publicly Traded Corporation?
If I Want to Establish a Money Purchase/Profit Sharing Plan, Do I Have to Establish One for All Owners of My Business?
What is Insider Trading?
What is the Federal Employee Retirement System (FERS)?
What is KOSPI and How Does It Reflect South Korea's Economic Landscape?
General Information
a provider of industry-specific, cloud-based software solutions for the life sciences industry
Industry ServicestotheHealthIndustry
Advertisement